英伟达与Arc研究所合作开发涵盖所有生命领域的遗传代码AI模型-动脉网

NVIDIA, Arc Institute partner on AI model with genetic code for all domains of life

MobiHealthNews 等信源发布 2025-02-25 18:33



可切换为仅中文







Photo:

照片：

Gorodenkoff Productions OU

戈罗登科夫制作公司OU

/Getty Images

/盖蒂图片社

Silicon Valley giant

硅谷巨头

NVIDIA

英伟达

announced a partnership with the Arc Institute and

宣布与Arc研究所和

Stanford University

斯坦福大学

to launch a new foundation model, Evo 2, that understands the genetic code for all domains of life.

推出一个新的基础模型Evo 2，该模型能够理解所有生命领域的遗传密码。

The model, which is being touted as the largest publicly available AI model for genomic data, was built using the NVIDIA DGX Cloud platform on

该模型被誉为最大的公开可用的基因组数据人工智能模型，是使用NVIDIA DGX Cloud平台构建的。

Amazon Web Services

亚马逊网络服务

(AWS) in collaboration with Arc and Stanford.

（AWS）与Arc和斯坦福大学合作。

According to NVIDIA, Evo 2 is accessible to global developers on the NVIDIA BioNeMo platform, including as an NVIDIA NIM microservice for easy and safe AI deployment.

根据NVIDIA的说法，Evo 2可以通过NVIDIA BioNeMo平台供全球开发者使用，包括作为NVIDIA NIM微服务，以便于安全地部署AI。

NVIDIA touts Evo 2 was trained on a huge dataset of nearly nine trillion nucleotides, the building blocks of DNA and RNA, and 'can be applied to biomolecular research applications including predicting the form and function of proteins based on their genetic sequence, identifying novel molecules for healthcare and industrial applications and evaluating how gene mutations affect their function.'.

NVIDIA 表示，Evo 2 模型训练使用了近九万亿个核苷酸的超大数据集，这些核苷酸是DNA和RNA的基本组成部分，并且“可应用于生物分子研究领域，包括根据基因序列预测蛋白质的结构和功能、识别用于医疗和工业应用的新型分子，以及评估基因突变对其功能的影响。”

Additionally, the NVIDIA NIM microservice for Evo 2 allows users to generate an assortment of biological sequences, with settings to adjust model parameters.

此外，Evo 2的NVIDIA NIM微服务允许用户生成各种生物序列，并提供设置以调整模型参数。

Meanwhile, developers who are interested in fine-tuning Evo 2 on their proprietary datasets can download the model via the open-source NVIDIA BioNeMo Framework, which is a collection of accelerated computing tools for biomolecular research.

同时，对在自己的专有数据集上微调 Evo 2 感兴趣的开发者可以通过开源的 NVIDIA BioNeMo 框架下载该模型，该框架是用于生物分子研究的加速计算工具集合。

'Evo 2 represents a major milestone for generative genomics,' Patrick Hsu, Arc Institute cofounder and core investigator and assistant professor of bioengineering at the University of California, Berkeley, said in a statement.

“Evo 2代表了生成基因组学的一个重要里程碑，”加州大学伯克利分校生物工程助理教授、Arc研究所联合创始人兼核心研究员帕特里克·许在一份声明中表示。

'By advancing our understanding of these fundamental building blocks of life, we can pursue solutions in healthcare and environmental science that are unimaginable today.'

“通过加深我们对这些生命基本组成部分的理解，我们可以追求当今无法想象的医疗保健和环境科学解决方案。”

Dave Burke, Arc’s chief technology officer, said that deploying a model like Evo 2 is like sending a powerful new telescope out to the farthest reaches of the universe.

戴夫·伯克，Arc的首席技术官表示，部署像Evo 2这样的模型，就如同将一台强大的新望远镜送至宇宙的最远端。

'We know there’s immense opportunity for exploration, but we don’t yet know what we’re going to discover,' Burke said in a statement.

“我们知道探索的机会非常大，但我们还不知道会发现什么，”伯克在一份声明中说。

The Arc Institute helps researchers to take on long-term scientific challenges by providing scientists with multi-year funding while at the same time letting scientists focus on creative research instead of grant writing.

Arc研究所通过为科学家提供多年资助，帮助研究人员应对长期的科学挑战，同时让科学家专注于创造性研究，而非撰写资助申请。

THE LARGER TREND

更大的趋势

In 2022, NVIDIA

2022年，英伟达

expanded its portfolio of products for healthcare with the launch of

通过推出新产品，扩大了其医疗保健产品组合

Clara Holoscan MGX

克拉拉全息计算MGX

, a tool designed to help medical device organizations develop artificial intelligence tools. The new technology was created to help industry players meet regulatory standards.

，一种旨在帮助医疗器械组织开发人工智能工具的工具。这项新技术的诞生是为了帮助行业参与者满足监管标准。

The platform builds on its previously launched product, the

该平台在其先前推出的产品基础上构建，

Clara Holoscan

克拉拉·霍洛斯坎

, which developed to give industry stakeholders a computational infrastructure to stream data from medical devices. According to the company, Clara Holoscan MGX is able to process 'high-throughput data streams for real-time insights.'

，该产品旨在为行业利益相关者提供一个计算基础设施，用于从医疗设备传输数据。据该公司称，Clara Holoscan MGX能够处理“高吞吐量数据流以提供实时洞察”。

In 2021, NVIDIA teamed up with pharma company

2021年，NVIDIA与制药公司联手

AstraZeneca

阿斯利康

and the

和

University of Florida

佛罗里达大学

打开

new artificial intelligence research projects

新的人工智能研究项目

that were aimed at boosting drug discovery and patient care.

旨在促进药物发现和患者护理。

NVIDIA and AstraZeneca revealed a new drug-discovery model called MegaMoIBART, which is aimed at 'reaction prediction, molecular optimization and de novo molecular generation.'

NVIDIA 和阿斯利康揭示了一种名为 MegaMoIBART 的新药物发现模型，该模型旨在“反应预测、分子优化和从头分子生成”。

MegaMoIBART was deployed on NVIDIA's platform for computational drug discovery,Clara Discovery and used a new kind of technology called transformer neural networks.

MegaMoIBART被部署在英伟达的计算药物发现平台Clara Discovery上，并使用了一种称为变压器神经网络的新技术。

That same year, NVIDIA joined forces with

同年，英伟达与

Harvard University

哈佛大学

on an

在

AI-based toolkit

基于人工智能的工具包

designed to help researchers gain more access and insights into DNA. Researchers were also able to run a whole genome analysis in 30 minutes.

旨在帮助研究人员获得更多关于DNA的访问和洞察。研究人员还能够在30分钟内运行全基因组分析。

The tool, AtacWorks, was able to identify specific sequencing data and pinpoint areas with easy-access DNA, meaning functional DNA that is not surrounded by proteins.

该工具名为AtacWorks，能够识别特定的测序数据，并精确定位到容易获取DNA的区域，这意味着未被蛋白质包围的功能性DNA。

This month, the Arc Institute launched the Arc Virtual Cell Atlas, a resource for computation-ready single-cell measurements, beginning with data from more than 300 cells.

本月，Arc研究所推出了Arc虚拟细胞图谱，这是一个计算就绪的单细胞测量资源，首先包含了来自300多个细胞的数据。

The initial release of the Atlas is Arc's first step toward assembling, curating and generating large-scale cellular data to fuel new insights from AI-driven biological discovery.

Atlas 的首次发布是 Arc 在组建、策划和生成大规模细胞数据以推动 AI 驱动的生物发现新见解方面的第一步。

Tags:

标签：

Nvidia

英伟达

，

Arc Institute

弧研究所

，

Stanford University

斯坦福大学

，